Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03686813 · ClinicalTrials.gov registry record · Phase 2
Sildenafil for Swimming-Induced Pulmonary Edema (SIPE) Prevention
A Phase 2 study of Edema, Pulmonary and Immersion, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT03686813 is a Phase 2 study of Edema, Pulmonary and Immersion that has completed, run by Duke University. The registered enrollment target is 18 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03686813, a Phase 2 study of Edema, Pulmonary and Immersion, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial is testing the effectiveness of a single oral dose of sildenafil (50 mg) taken 1 hour before a provocative event on the subsequent development of swimming-induced pulmonary edema.
Conditions Studied
Interventions
- DRUG Placebo Oral Tablet
- DRUG Sildenafil Citrate
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2021-10-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03686813
The ClinicalTrials.gov registry entry for NCT03686813 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Edema, Pulmonary appearing as the primary indexed condition, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03686813 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT03686813 about?
NCT03686813 is a clinical study titled "Sildenafil for Swimming-Induced Pulmonary Edema (SIPE) Prevention". This trial is testing the effectiveness of a single oral dose of sildenafil (50 mg) taken 1 hour before a provocative event on the subsequent development of swimming-induced pulmonary edema.
What is the current status of trial NCT03686813?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2019-07-15. Estimated completion is 2021-10-29.
What conditions does trial NCT03686813 study?
This clinical trial studies the following conditions: Edema, Pulmonary, Immersion, Diving.
What interventions are being tested in trial NCT03686813?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Sildenafil Citrate (DRUG).
Who is sponsoring clinical trial NCT03686813?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03686813 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.